Professional
Added to YB: 2024-09-30
Pitch date: 2024-09-27
PFE [bullish]
Pfizer Inc.
+2.17%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
Market Cap
$155.6B
Pitch Price
$26.29
Price Target
42.00 (+56%)
Dividend
6.28%
EV/EBITDA
7.90
P/E
20.13
EV/Sales
3.24
Sector
Pharmaceuticals
Category
value
Show full summary:
Pfizer Inc.: Pfizer's Diverse Portfolio of Drugs and Vaccines Supports a Wide Moat
PFE: Wide moat from diverse drugs, strong cash flows & R&D. 2020 Upjohn spinoff accelerates growth. Covid-19 success but declining sales. Key drugs: Prevnar, Eliquis, Ibrance. Risks: generic competition, drug pricing policy. FV $42. Medium uncertainty. Cost cuts of $4B by 2024-end. Standard capital allocation.